SEC Form 4 · accession 0001209191-18-021367
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Jason Douglas Wilson
Officer — Chief Financial Officer
Period of report
Mar 23, 2018
Accepted (ET)
Mar 23, 2018 · 1:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B common stockF1 | — | Mar 23, 2018 | M | 930 | A | — | — | Class A common stock | 930 | 67,666 | D |
| Class B common stockF1 | — | Mar 23, 2018 | M | 210 | A | — | — | Class A common stock | 210 | 67,876 | D |
| Employee Stock Option (right to buy)F2,F1 | $8.11 | Mar 23, 2018 | M | 930 | D | — | Feb 3, 2019 | Class B common stock | 930 | 0 | D |
| Employee Stock Option (right to buy)F3,F1 | $11.62 | Mar 23, 2018 | M | 210 | D | — | Jun 15, 2023 | Class B common stock | 210 | 0 | D |
Explanation of responses
- F1The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time.
- F2The options vested in sixteen equal quarterly installments beginning on May 3, 2009.
- F3The options vest in twenty equal quarterly installments beginning on June 15, 2013, subject to continued service through each vesting date.